Prediction of Lymphatic Metastasis in Esophageal Cancer by CT Radiomics
1 other identifier
observational
133
1 country
1
Brief Summary
This study proposes to establish a CT radiomics-based prediction model for identifying metastasis lymph nodes in esophageal cancer.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Feb 2017
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 15, 2017
CompletedFirst Submitted
Initial submission to the registry
July 31, 2017
CompletedFirst Posted
Study publicly available on registry
August 2, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 7, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
May 15, 2020
CompletedFebruary 2, 2021
January 1, 2021
2.7 years
July 31, 2017
January 31, 2021
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
pathological local lymph node status
pathological lymph node status is defined as lymph node metastasis exist or not
Pathologic evaluation will be performed for each patient within 1 week after surgery
Study Arms (1)
preoperative enhanced chest CT
The cohort contains patients with preoperative therapies and patients without preoperative therapies. Each patient receives regular preoperative enhanced chest CT; for patients with preoperative therapies, they usually undergo twice enhanced chest CT examination at before and after preoperative therapies, the CT images after preoperative therapies will be used for analysis
Interventions
Each patient will receive preoperative enhanced chest CT examination, and their CT images will be used for analysis
Eligibility Criteria
pathologically proven esophageal cancer patients who receive preoperative CT and surgical resection in our hospital.
You may qualify if:
- pathologically proven esophageal cancer
- scheduled to preoperative enhanced chest CT and undergo surgery
- sign the patient informed consent
You may not qualify if:
- failed to receive preoperative enhanced chest CT or undergo surgery
- inavailable pathological results for local lymph node status
- inquality of CT images for feature extraction
- patient quit
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Beijing Cancer Hospital
Beijing, Beijing Municipality, 100142, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Ying-Shi Sun, MD
Dept.Radiology,Peking University Cancer Hospital
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Chairman of Dept.Radiology of Beijing Cancer Hospital
Study Record Dates
First Submitted
July 31, 2017
First Posted
August 2, 2017
Study Start
February 15, 2017
Primary Completion
November 7, 2019
Study Completion
May 15, 2020
Last Updated
February 2, 2021
Record last verified: 2021-01